

REMARKS

Applicants here responds to the Office Action mailed April 23, 2003. To overcome the rejections under Section 112(1) and (2), applicants have limited independent claims 86 and 94, and all remaining claims dependent thereon, to specific disorders of the central nervous system, and has further limited the steps involving the administration of drugs. Applicants have amended claim 100 to delete reference to a growth hormone releasing substance.

The dependent claims at issue refer to drugs that were known at the time applicants filed this application. The specification provides examples of these drugs. Since patent applications are directed to those skilled in the art, and are not intended to provide an exhaustive or encyclopedic discussion of prior art drugs, applicants should not be required to limit these claims to specific drugs that serve the claimed anti-viral, anti-fungal, antibiotic, etc. purposes.

Responding to the rejections of the claims based upon Baumzweiger (3), Baumzweiger (3) was not published more than a year before applicants' effective filing date. Therefore, Baumzweiger (3) is not prior art against this application.

Baumzweiger (4) does not disclose or suggest the steps called for in

applicants' claims, except for administering calcium channel blockers.

Applicants' counsel would welcome a telephone call from Dr. Travers at any time to discuss any issue.

Respectfully submitted,



Dated: October 23, 2003

Patrick F. Bright,
Reg. No. 24,318
BRIGHT & LORIG, P.C.
633 West 5th St., Ste 3330
Los Angeles, CA 90071
Tel: 213.627.7774
Fax: 213.627.8508